Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf-based immunosuppression with or without corticosteroids in kidney transplant recipients: incidence of new-onset diabetes mellitus
2010-019638-28Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence of new-onset diabetes mellitus. Started Sep 2010; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2010-019638-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019638-28.